Compare Conagra Brands Inc (CAG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs Recursion Pharmaceuticals Inc — how do they compare? Conagra Brands Inc trades at $14.93 (market cap $7.14B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Conagra Brands Inc is far larger — about 3.9× Recursion Pharmaceuticals Inc's market cap, and Conagra Brands Inc pays a 8.2% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CAG | RXRX | |
|---|---|---|
Market Cap | $7.14B | $1.81B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $6.79 |
52-Week Low | $12.58 | $2.84 |
Enterprise Value | $14.20B | $1.33B |
Dividend Yield | 8.2% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
